The recent announcement of the 2023 Nobel Prize in Physiology or Medicine has turned attention again to RNA therapeutic vaccines and a better understanding of RNA biology.
The recent announcement of the 2023 Nobel Prize in Physiology or Medicine has turned attention again to RNA therapeutic vaccines and a better understanding of RNA biology. Despite a skeptical scientific community, the 2 awardees, Katalin Karikó, PhD, and Drew Weissman, MD, PhD, persevered with their findings that labile RNA fragments could effectively translate into human immunotherapy. Indeed, several companies demonstrated that RNAs were sufficiently stable and could be very rapidly modified, a feature that turned out to be crucial during the early and terrifying months of the global COVID-19 pandemic. With a strong, concerted effort that led to its eventual use in the clinic, and through collaboration with scientists and pharmaceutical companies worldwide, the translation of rapid antigen discovery and molecular biology created lifesaving and life-prolonging COVID-19 vaccines.
Now that these RNA vaccines will take their place alongside the influenza vaccine, which is based on a protein subunit-based strategy, what are the implications for cancer immunotherapy and vaccines?
A couple of factors are in play. One is the amount of investment that has been poured into this RNA-based platform; another is a sense of rapidity as pattern recognition and innate inflammatory signals move moieties that are conferred through an attuned antigen and adjuvant strategy, and paved the way for various manipulable genetically engineered cancer vaccines.
Quick development is warranted, given the need for personalized vaccines after whole exome sequencing and other tumor antigen-specific approaches that must conform to the time frame of a patient with recurrent or metastatic disease who needs their tumor genomically profiled.
Thus, the scientific community is leveraging knowledge of infectious disease, much as the medical field advanced during the HIV epidemic 30 years ago, to clarify the cancer immunotherapy and vaccination approach. This is a time to reflect and remind ourselves not to disregard scientific or clinical outcomes that may seem obvious, because ultimately the experiment always needs to be performed and trialed in humans, and sometimes crisis is the mother of opportunity and accomplishment.
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More